Cardiff Oncology (CRDF) said Tuesday its oversubscribed public offering of nearly 15.4 million common shares has been priced at $2.60 apiece.
The offering, which will likely close on or about Wednesday, is expected to generate roughly $40 million in gross proceeds that will be used for working capital and other general corporate purposes, among other uses, the company said.
Cardiff Oncology shares were up over 33% in recent Tuesday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments